Vanda Pharmaceuticals Inc. (VNDA)
After hours:
| Previous close | 4.8800 |
| Open | 4.9900 |
| Bid | 4.8300 x 500 |
| Ask | 4.8600 x 300 |
| Day's range | 4.7900 - 5.0319 |
| 52-week range | 3.3000 - 6.9200 |
| Volume | |
| Avg. volume | 2,418,213 |
| Market cap | 281.677M |
| Beta (5Y monthly) | 0.78 |
| PE ratio (TTM) | 121.00 |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- PR Newswire
Vanda Pharmaceuticals to Announce First Quarter 2024 Financial Results on May 8, 2024
Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced it will release results for the first quarter 2024 on Wednesday, May 8, 2024, after the market closes.
- GlobeNewswire
Shareholder Capital Delivers Letter to Independent Members of the Board of Vanda Pharmaceuticals
Reminds Vanda’s Board of Their Fiduciary Duties Given the Mishandling of Future Pak’s Offer to Acquire Vanda’s Underperforming and Undervalued Shares at an ~80-90% Premium Expresses Serious Concerns Over Entrenchment, Misaligned Incentives, and Cronyism at Vanda, Including the CEO’s and His Family’s $46M+ in Disclosed Compensation Amidst $1B+ in Shareholder Value Destruction Believes Vanda’s Board Must Explore Strategic Alternatives MIAMI, April 25, 2024 (GLOBE NEWSWIRE) -- Shareholder Capital L
- PR Newswire
Vanda Pharmaceuticals Reacts to U.S. Supreme Court's Denial of its Petition in HETLIOZ® ANDA Litigation
Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that the Supreme Court denied Vanda's petition for a writ of certiorari in its HETLIOZ® Abbreviated New Drug Application litigation against Teva Pharmaceuticals USA, Inc., Apotex Inc. and Apotex Corp.
